Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections.[1][2] If approved it would be a first-in-class medication (for the orotomide class). In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug.[3] Olorofim does not inhibit growth of Candida species.[2]

Olorofim
Clinical data
Other namesF901318
Legal status
Legal status
  • Investigational
Identifiers
  • 2-(1,5-Dimethyl-3-phenylpyrrol-2-yl)-N-[4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl]-2-oxoacetamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H27FN6O2
Molar mass498.562 g·mol−1

References

edit
  1. ^ Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577–594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.
  2. ^ a b Wiederhold, Nathan P. (2020). "Review of the Novel Investigational Antifungal Olorofim". Journal of Fungi. 6 (3): 122. doi:10.3390/jof6030122. ISSN 2309-608X. PMC 7557671. PMID 32751765.
  3. ^ "FDA Passes on Olorofim Despite Critical Need for Antifungals". Medscape.